Detalhe da pesquisa
1.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
2.
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Cancer Immunol Immunother
; 72(5): 1153-1167, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36355079
3.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37132225
4.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
5.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388396
6.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
7.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
8.
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.
Eur J Haematol
; 109(6): 749-754, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066204
9.
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
Eur J Haematol
; 108(1): 34-44, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34536308
10.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
11.
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Blood
; 134(8): 668-677, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270103
12.
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Haematologica
; 106(6): 1725-1732, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32354874
13.
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Ann Hematol
; 100(4): 1065-1077, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599794
14.
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.
Eur J Haematol
; 106(4): 546-554, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33471414
15.
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma.
Am J Hematol
; 96(1): 23-30, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32936979
16.
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
Am J Hematol
; 96(8): 925-933, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33901326
17.
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden.
Acta Haematol
; 144(5): 519-527, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33631745
18.
Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.
Blood
; 131(19): 2138-2150, 2018 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519805
19.
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Eur J Haematol
; 105(6): 751-754, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745304
20.
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment.
Eur J Haematol
; 105(2): 196-202, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32281193